The study, co-authored by Seqirus, was conducted as part of a Phase III clinical trial of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK.
The co-administration sub-study enrolled a total of 431 volunteers, all of whom had received a flu vaccine provided by Seqirus.
Following this, approximately half of the volunteers also received NVX-CoV2373, while the rest received a placebo jab.
The study results, published on the pre-print server medRxiv, suggest that the efficacy of both the flu vaccine and the COVID-19 vaccine appeared to be preserved, with no additional safety concerns appearing with co-administration.
